N

    NuCana PLC (NCNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.47
    -0.29 (-16.48%)

    Market Cap: $7.33M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(22/35)
    Avg Surprise
    +17.98%
    Streak
    3 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.99N/AN/ABeat+95.8%
    Mar 26
    		$-1.25N/A+52.72%Beat-143.7%
    Dec 25
    		$-1.47$-2.69+45.44%Beat+97.7%
    Sep 25
    		$-0.08N/A+99.38%Beat+100.0%
    Jun 25
    		$-23.31$-13.00-79.31%Miss+97.0%
    Mar 25
    		$-0.51N/A+96.05%Beat+99.9%
    Dec 24
    		$-64.85N/A+85.26%Beat+81.5%
    Sep 24
    		$-439.60$-790.00+44.35%Beat+45.5%
    Jun 24
    		$-771.80$-798.00+3.28%Beat-21.1%
    Mar 24
    		$-823.60$-820.00-0.44%Miss+12.0%
    Dec 23
    		$-350.00$-254.95-37.28%Miss-29166566.7%
    Sep 23
    		$-807.15$-612.50-31.78%Miss-51.0%
    Jun 23
    		$-637.55$-810.00+21.29%Beat-51.2%
    Mar 23
    		$-935.80$-717.50-30.43%Miss+6.8%
    Dec 22
    		$-0.00$-0.00+0.00%Beat+100.0%
    Sep 22
    		$-534.70$-620.00+13.76%Beat+47.1%
    Jun 22
    		$-421.60$-752.50+43.97%Beat+63.7%
    Mar 22
    		$-1004.05$-745.00-34.77%Miss+25.3%
    Dec 21
    		$-21.00$-19.81-6.01%Miss+12.5%
    Sep 21
    		$-1010.45$-1226.67+17.63%Beat+36.4%
    Jun 21
    		$-1161.40$-1345.00+13.65%Beat+7.3%
    Mar 21
    		$-1345.00$-1143.75-17.60%Miss-83.1%
    Dec 20
    		$-24.00$-16.11-48.98%Miss+0.0%
    Sep 20
    		$-1587.55$-1217.00-30.45%Miss-106.0%
    Jun 20
    		$-1252.85$-1118.00-12.06%Miss-47.4%
    Mar 20
    		$-734.60$-1149.00+36.07%Beat+33.1%
    Dec 19
    		$-24.00$-16.20-48.15%Miss-118.2%
    Sep 19
    		$-770.70$-1422.00+45.80%Beat-51.1%
    Jun 19
    		$-849.80$-1192.00+28.71%Beat-229.8%
    Mar 19
    		$-1097.45$-1306.67+16.01%Beat+17.8%
    Dec 18
    		$-11.00$-19.05+42.26%Beat-1406.8%
    Sep 18
    		$-509.90N/A+63.61%Beat-6798566.7%
    Jun 18
    		$-257.65N/A+80.36%Beat-183935.7%
    Mar 18
    		$-1335.25$-1092.50-22.22%Miss-1907400.0%
    Dec 17
    		$-0.73N/A+91.80%Beat-265.0%
    Sep 17
    		$-0.01N/A+87.50%Beat-
    Jun 17
    		$-0.14N/AN/ABeat-
    Mar 17
    		$-0.07$0.00N/AMiss-
    Dec 16
    		$-0.20$0.00N/AMiss-
    Sep 16
    		$0.00N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.39EV/EBITDA0.30x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-70.30%ROIC-111.05%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.73xQuick Ratio4.73x
    Trading Statistics
    Beta2.22Avg Volume88.69K
    52-Week High$7.2252-Week Low$1.21

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.53
    SMA 20$1.49
    SMA 50$1.43
    SMA 200$2.29
    EMA 10$1.53
    EMA 20$1.49
    EMA 50$1.53
    EMA 200$8.76

    MACD

    Line: 0.03Signal: 0.02Hist: 0.01

    ADX

    ADX: 39.6+DI: 34.5-DI: 7.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down8.0
    PSAR$1.41

    Bollinger Bands

    Upper Band$1.67
    Lower Band$1.31
    %B Position2428%(Upper)
    Band Width0.45

    RSI (14-Day)

    Neutral
    49.2

    Momentum Oscillators

    Stoch %K37.5
    Stoch %D44.8
    Williams %R-86.0
    ROC (10d)-5.2%
    Momentum-0.08
    CCI (20d)-7.9
    MFI (14d)78.9

    Volatility Measures

    ATR (14d)$0.14(9.6%)
    StdDev (20d)0.09
    Hist Vol107.6%(High)

    Volume Flow

    VWAP$1.49
    OBV5.9B
    AD Line26824.3B
    CMF (20d)0.119

    Volume Metrics

    Avg Vol (20d)91.8K
    Vol Ratio2.1x(High)
    VWMA (20d)$1.64

    Pivot Points

    R3$2.46
    R2$2.18
    R1$1.97
    Pivot Point$1.69
    S1$1.48
    S2$1.20
    S3$0.99

    Advanced Oscillators

    TSI9.68
    Ultimate Osc42.6
    KST135.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$71,368$69,482$68,102N/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross Profit$-71,368$-69,482$-68,102N/AN/AN/AN/AN/AN/AN/AN/AN/A
    Operating Expenses$3.38M$4.42M$2.74M$779,000$11.83M$2.85M$865,000$5.32M$8.35M$8.27M$9.11M$8.25M
    R&D$2.26M$3.21M$1.74M$2.17M$7.10M$1.73M$729,000$3.74M$6.77M$6.78M$6.86M$7.44M
    SG&A$0$1.57M$1.11M$1.40M$4.52M$1.07M$540,000$1.36M$1.51M$1.58M$1.29M$1.38M
    Operating Income$-3,454,860$-4,418,000$-2,806,018$-779,000$-11,829,000$-2,851,000$-865,000$-5,323,000$-8,352,000$-8,269,000$-9,107,000$-8,252,000
    Interest Income$0$143,000$173,000$153,000$35,000$25,000$75,000$72,000$85,000$126,000$137,000$152,000
    Interest Expense$0$0$0$0$12.61M$0$0$0$0$0$0$0
    Income Before Tax$-3,430,735$-4,275,000$-2,592,827$-626,000$-24,442,000$-2,826,000$-790,000$-5,251,000$-8,267,000$-8,143,000$-8,970,000$-8,100,000
    Income Tax Expense$-334,729$-410,000$-140,152$-345,000$-328,000$-353,000$-137,000$-740,000$-1,272,000$-1,305,000$-1,315,000$-1,404,000
    Net Income$-3,096,005$-3,865,000$-2,452,675$-281,000$-24,114,000$-2,473,000$-653,000$-4,511,000$-6,995,000$-6,838,000$-7,655,000$-6,696,000
    EBITDA$-3,383,491$-4,713,000$-2,737,916$-3,502,000$-11,558,000$-2,725,000$-1,154,000$-4,959,000$-8,142,000$-8,228,000$-8,004,000$-8,668,000
    EBIT$-3,454,859$-4,781,000$-2,806,018$-3,571,000$-11,627,000$-2,792,000$-1,269,000$-5,094,000$-8,278,000$-8,364,000$-8,145,000$-8,814,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NCNA

    News

    NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

    NuCana (NASDAQ: NCNA) announced its financial results for the second quarter of 2026, reporting a net loss of £3.1 million and stating that its cash reserves are expected to fund operations into 2029. The company completed recruitment for its Phase 2 expansion study of NUC-7738 in combination with Keytruda for metastatic melanoma and anticipates releasing final data later in 2026. NuCana also plans to seek regulatory guidance from the FDA for a potential registrational strategy for NUC-7738 and is exploring additional indications and combination strategies for both NUC-7738 and NUC-3373.

    The Manila Times•8/14/26•
    Bullish

    NuCana Q2 Results: Net loss narrows 87% YoY to £3.1 million

    NuCana plc reported a significant narrowing of its net loss for Q2 2026, down 87% year-over-year to £3.1 million, primarily due to lower operating expenses and the absence of non-cash warrant revaluation charges. The company's strong cash position of £19.5 million is projected to fund operations through 2029, as it advances its clinical program for NUC-7738 in metastatic melanoma. NuCana completed patient recruitment for its Phase 2 study of NUC-7738 and is planning its registrational strategy with the FDA.

    scanx.trade•8/13/26•
    Bullish

    NuCana completes melanoma study enrollment; final data expected in 2026

    NuCana (NASDAQ: NCNA) reported its Q2 2026 financial results, showing a significantly reduced net loss of £3.1 million, down from £24.1 million in Q2 2025, with cash and cash equivalents of £19.5 million expected to fund operations into 2029. The company also announced the completion of patient recruitment for its Phase 2 NuTide:701 expansion study for NUC-7738 in metastatic melanoma, with final data anticipated later in 2026 and ongoing discussions with the FDA for a potential registrational path. NuCana is also exploring additional indications for NUC-7738 and optimizing its strategy for NUC-3373.

    Stock Titan•8/13/26•
    Somewhat-Bullish

    NuCana publishes corporate presentation on ProTide-based oncology pipeline

    NuCana has released a corporate presentation detailing its ProTide-based oncology pipeline, highlighting NUC-7738 as its lead program aimed at improving responses to PD-(L)1 inhibitors in resistant tumors. The company reported promising monotherapy data for NuTide:701, showing a 41% disease control rate with no Grade 4 toxicities, and noted significant tumor reductions in melanoma patients treated with NUC-7738 in combination with pembrolizumab. NuCana also confirmed cash and cash equivalents of approximately $28.4 million as of March 31, 2026, projecting a financial runway into 2029.

    Bitget•8/8/26•
    Bullish

    NuCana PLC (NCNA) Stock News Today

    This article provides the latest stock news for NuCana PLC (NCNA) on TradingKey. It displays current stock performance, market capitalization, and P/E ratio, noting an 8.09% increase. The page indicates that more news will be coming soon for the company.

    TradingKey•8/7/26•
    Bullish

    Frequently Asked Questions About NCNA

    Does NCNA pay dividends?
    NuCana PLC (NCNA) does not currently pay a regular dividend.
    What is NCNA's market cap?
    NuCana PLC (NCNA) has a market capitalization of $7.33M with a current stock price of $1.47.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In